TyraTech notessales of Vamousse progress

28th Jul 2016 13:24

(ShareCast News) - Life-sciences company TyraTech said its first-half trading performance continues the upward trend from prior periods, with unit sales of the Vamousse head-lice product line continuing to progress and operating-expense efficiencies now being realised."These trends are anticipated to continue throughout the second half. The board expects the net loss over the year to remain in line with current market expectations," TyraTech said.It added that Vamousse unit sales were in line with expectations, showing strong growth over the corresponding period for 2015 across all geographies and customers."Vamousse continues to establish itself as a leading brand and is performing well in the market against competitor products, gaining market share," the company said."Revenues associated with these sales have been modestly impacted by currency translation effects on UK sales and by revenue recognition factors, due to sale or return associated with one new US customer. These impacts are expected to continue through the rest of the year."TyraTech added that the PureScience portfolio of animal health products was showing good results in field and customer trials, and three products were launched for poultry and swine production at the end of the half."The roll-out of PureScience in the first half was slower than anticipated mainly due to the time of completing the field trials and it is now expected that the revenue impact will be in the second half of the year."